Publications

Branded pharmaceutical manufacturers frequently offer “copay coupons” that insulate consumers from cost-sharing, thereby undermining insurers’ ability to influence drug utilization. We study the impact of copay coupons on branded drugs first facing generic entry... View Details

Amy W. Schulman

Amy W. Schulman joined Harvard Business School’s Faculty as a Senior Lecturer in July 2014.

In addition to her responsibilities at Harvard, Ms. Schulman is a managing partner at Polaris Partners, who focuses on investing in healthcare... View Details

September 2023 (Revised December 2023)
Case

TetraScience: Noise and Signal

By: Thomas R. Eisenmann and Tom Quinn

In 2019, TetraScience CEO “Spin” Wang needed advice. Five years earlier, he had cofounded a startup that saw early success with a hardware product designed to help laboratory scientists in the biotechnology and pharmaceutical spaces more easily collect data from... View Details

Keywords: Entrepreneurship; Business Growth and Maturation; Business Organization; Restructuring; Forecasting and Prediction; Digital Platforms; Analytics and Data Science; AI and Machine Learning; Organizational Structure; Network Effects; Competitive Strategy; Pharmaceutical Industry; Pharmaceutical Industry; United States; Boston

September 2014
Case

Pfizer's Centers for Therapeutic Innovation (CTI)

By: Gary Pisano, James Weber and Kait Szydlowski

In 2010, Pfizer established four small research units in New York, Boston, San Francisco, and San Diego located close to several premier Academic Medical Centers (AMCs), or hospitals with adjoining medical schools. The goal of these units was to redesign collaboration... View Details

Keywords: Drug Development; Academic Collaboration; Research And Development; Innovation; Translational Research; Management; Operations; Problems and Challenges; Research; Science; Information Technology; Strategy; Pharmaceutical Industry; Pharmaceutical Industry; North and Central America; Europe; Asia

December 1997
Case

American Cyanamid (A) & (B) (Combined)

American Home Products' (AHP) $9 billion hostile takeover of American Cyanamid (Cyanamid) was the largest merger-and-acquistion transaction in 1994, and made AHP the fourth largest pharmaceutical firm in the United States. At the time of AHP's offer, Cyanamid had... View Details

Keywords: Governing and Advisory Boards; Mergers and Acquisitions; Corporate Governance; Conflict and Resolution; Pharmaceutical Industry

2015
Working Paper

Public R&D Investments and Private-sector Patenting: Evidence from NIH Funding Rules

By: Pierre Azoulay, Joshua S. Graff Zivin, Danielle Li and Bhaven N. Sampat

We quantify the impact of scientific grant funding at the National Institutes of Health (NIH) on patenting by pharmaceutical and biotechnology firms. Our paper makes two contributions. First, we use newly constructed bibliometric data to develop a method for flexibly... View Details

Keywords: Economics Of Science; Patenting; Academic Reserach; NIH; Knowledge Spillovers; Patents; Research; Government and Politics

Read Now

March 2008 (Revised July 2011)
Supplement

Cadbury Schweppes: Capturing Confectionery (D)

By: David Collis, Toby Stuart and Troy Smith

In late 2002, global confectionery and beverage maker Cadbury Schweppes needed to decide whether or not to make an acquisition bid for Adams, an underperforming gum company which had been put up for sale by pharmaceutical giant Pfizer. Examining the decision from a... View Details

Keywords: Food; Mergers and Acquisitions; Corporate Strategy

March 2008 (Revised January 2023)
Supplement

Cadbury Schweppes: Capturing Confectionery (B)

By: David Collis, Toby Stuart and Troy Smith

In late 2002, global confectionery and beverage maker Cadbury Schweppes needed to decide whether or not to make an acquisition bid for Adams, an underperforming gum company which had been put up for sale by pharmaceutical giant Pfizer. Examining the decision from a... View Details

Keywords: Food; Mergers and Acquisitions; Corporate Strategy; Food and Beverage Industry

October 2023 (Revised May 2024)
Case

Thermo Fisher Scientific: Foray into Contract Research

By: Satish Tadikonda, William Marks and Kevin Emancipator

After publicly declaring that they would not enter the contract research organization (CRO) business in 2017, Thermo Fisher purchased Pharmaceutical Product Development (PPD), one of the biggest players in the CRO space, in 2021. Much had changed in the intervening... View Details

Keywords: Mergers and Acquisitions; Customer Focus and Relationships; Corporate Strategy; Organizational Change and Adaptation; Biotechnology Industry

Research Summary

Overview

By: Kyle R. Myers

Professor Myers studies the economics of what determines the rate and direction of innovation. He has examined the reallocation of scientists through the use of targeted research grants at the National Institutes of Health, and is working to further understand how... View Details

September 1993
Case

Manufacturing at ALZA: The Right Prescription? (A)

By: Dorothy A. Leonard

ALZA, a company specializing in drug delivery systems such as transdermal patches, considers manufacturing its own products. Until now, the company has conducted research and development on its patented system but has then licensed the technology to client-partner... View Details

Keywords: Business or Company Management; Technological Innovation; Innovation and Management; Growth and Development Strategy; Problems and Challenges; Production; Research and Development; Organizational Change and Adaptation; Pharmaceutical Industry; Pharmaceutical Industry

Find at Harvard

March 2008 (Revised July 2011)
Supplement

Cadbury Schweppes: Capturing Confectionery (C)

By: David Collis, Toby Stuart and Troy Smith

In late 2002, global confectionery and beverage maker Cadbury Schweppes needed to decide whether or not to make an acquisition bid for Adams, an underperforming gum company which had been put up for sale by pharmaceutical giant Pfizer. Examining the decision from a... View Details

Keywords: Food; Mergers and Acquisitions; Corporate Strategy; Food and Beverage Industry

Article

Beyond Magic Bullets: True Innovation in Health Care

By: Vaibhav A. Narayan, Marco Mohwinckel, Gary Pisano, Michael Yang and Husseini Manji

The molecular medicine revolution—based on advances in fields such as genomics and network modeling in the decade since the human genome sequence was completed—has changed the way we think about, study, and approach the development of novel therapies. However, these... View Details

Keywords: Integration; Business Model; Organizational Structure; Health Care and Treatment; Innovation and Invention; Pharmaceutical Industry

Find at Harvard

03 Apr 2007
First Look

First Look: April 3, 2007

drug discovery organization at Wyeth Pharmaceuticals and focuses on the decisions to: (1) centralize decision-making within drug discovery and (2) institute numerical metrics—jointly affecting all R&D scientists—for the progression of... View Details

Keywords: Martha Lagace

18 Apr 2024
Lecture

Innovation Opportunities Created by COVID-19 Can Help: And How to Make Them Happen

By: Regina E. Herzlinger

The crush of patients created by COVID enabled the creation of sites for care outside the traditional hospital, such as retail pharmacies, ambulatory surgery centers, urgent care centers, telemedicine, and wireless sensors. Public policy mirrored these changes by... View Details

Keywords: Policy; Health Pandemics; Health Care and Treatment; Innovation and Invention; Health Industry; Insurance Industry

12 Feb 2008
First Look

First Look: February 12, 2007

knowledge management into the future of Danone. Purchase this case: http://www.hbsp.harvard.edu/b01/en/common/item_detail.jhtml?id=608067 Ligand Pharmaceuticals Incorporated Harvard Business School Case 208-019 In an activist role, the... View Details

Keywords: Martha Lagace

January 2023 (Revised August 2023)
Case

Veeva Systems and the Transformation to a Public Benefit Corporation

By: Ranjay Gulati and Allison M. Ciechanover

Peter Gassner, the co-founder and CEO of Veeva Systems, steered the company through rapid scaling from its launch in 2007 to 2022. Year after year, the company had exceeded expectations, with its market capitalization reaching $50 billion at its peak. By 2022, the... View Details

Keywords: Transformation; Corporate Governance; Corporate Social Responsibility and Impact; Mission and Purpose; Organizational Culture; Information Technology Industry; Technology Industry; United States; California